An interview with Chris Silva, VP Global Marketing and Product, Carterra

November 9, 2022

Carterra is delivering a whole new way of screening and analyzing antibodies, pushing the limits in discovery of novel therapeutic candidates. Their solutions condense months of work into a few days. Carterra recently joined the Tetra Partner Network. Thankfully, we were able to catch Chris Silva, VP Global Marketing and Product, in between customer visits so that we can share their remarkable story.

In a sentence or two, what does Carterra do?

Carterra enables high-resolution antibody screening and characterization in a single step allowing biopharmaceutical companies to select drug candidates directly for their antibody library within 90 days or less. Carterra’ s proprietary high-throughput surface plasmon resonance (HT-SPR) technology delivers 100 times the data in 10% of the time, using 1% of the sample requirements of other label-free platforms.  The technology was instrumental in recently bringing two therapeutics to the market by Eli Lilly.

In what ways are your products and software advancing scientific research?

The Carterra LSA instrument and industry-leading analysis software, enabling epitope binning and kinetic analyses, allow our customers to push the limits of what can be done in terms of throughput, time, and efficiency. The ability to effectively screen a large library of antibodies and understand affinity, kinetics, specificity, and epitope information, allows scientists to pick relevant drug candidates earlier in the process.  Entire areas of study would not be possible and economically feasible without the high-resolution capabilities and cost efficiencies the LSA enables.

Read the Full Interview